IP Library › Granted Patent US 8,796,203
Granted Patent B2
US 8,796,203 · App. 13/625,293 · Granted Aug 5, 2014

Use of tight junction antagonists to treat inflammatory bowel disease

Inventors: Blake Paterson (Baltimore, MD); Amir Tamiz (Silver Spring, MD); Niranjan Pandey (White Marsh, MD)
Assignee: Alba Therapeutics Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,796,203
App. No.
13/625,293
Granted
Aug 5, 2014
Kind
B2
Abstract

The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents.

Claims (15)

1. A method for treating Inflammatory Bowel Disease (IBD) in a patient, the method comprising:

administering a peptide having the amino acid sequence GGVLVQPG (SEQ ID NO:15) to the colon of a patient having IBD.

2. The method of claim 1 , wherein the peptide is administered in a delayed release composition that is stable in gastric fluid.

3. The method of claim 1 , wherein the patient has Crohn's Disease.

4. The method of claim 1 , wherein the patient has ulcerative colitis.

5. The method of claim 1 , wherein the peptide is further administered to the small intestine of the patient.

6. The method of claim 1 , further comprising, administering an active agent selected from an aminosalicylate, corticosteroid, immunomodulator, or antibiotic.

7. The method of claim 6 , wherein the aminosalicylate is 5-aminosalicylic acid (5-ASA).

8. The method of claim 1 , wherein the peptide is administered one or more times per day for a plurality of days.

9. The method of claim 8 , wherein the peptide is administered chronically.

10. The method of claim 1 , wherein the patient is not undergoing an acute Inflammatory Bowel Disease (IBD) attack at the time the peptide is administered.

11. The method of claim 1 , wherein the patient is undergoing an acute attack of Inflammatory Bowel Disease (IBD) at the time the peptide is administered.

12. The method of claim 1 , wherein the patient is a human.

13. The method of claim 1 , wherein the patient is a dog.

14. A method for treating chronic Inflammatory Bowel Disease (IBD) in a patient in need thereof, the method comprising: administering to the patient one or more times per day for a plurality of days, a peptide having the amino acid sequence GGVLVQPG (SEQ ID NO:15), the peptide being administered in a delayed release composition to the colon of the subject.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2024
From: ALBA THERAPEUTICS CORPORATION
To: INTERLUDE BIOPHARMA CO
Reel/Frame 069653/0901 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2014
From: PATERSON, BLAKE; TAMIZ, AMIR; PANDEY, NIRANJAN
To: ALBA THERAPEUTICS CORP.
Reel/Frame 033038/0433 →
Continuity (6)
Continuation 12789081 · May 27, 2010
Continuation 11869230 · Oct 9, 2007
Provisional Application 60916412 · May 7, 2007
Provisional Application 60851318 · Oct 13, 2006
Provisional Application 60849802 · Oct 6, 2006
Related Publication 20130102547A1 · Apr 25, 2013